"Honeymoon, shunnymoon, I'm on my way!" the bride told a volunteer at Craven Wildlife Rescue, per the BBC ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and ...
An experimental inhibitor regrew cartilage in aged mice, opening up an alternative to arthritis and prosthetics.
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an ...
The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...
The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...
The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
Researchers have built a realistic human mini spinal cord in the lab and used it to simulate traumatic injury. The model reproduced key damage seen in real spinal cord injuries, including inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results